Try our corporate solution for free!
(212) 419-8286

Public drug program spending in Canada by top 10 drug classes 2019

This statistic displays the total public drug program expenditures in Canada in the top 10 drug classes in 2019. During this year, HMG-CoA reductase inhibitors (statins) which are often used for treating high cholesterol accounted for over 307 million Canadian dollars in public drug expenditures.

Leading 10 drug classes by total public drug program spending in Canada in 2019*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until May 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

December 2020



Survey time period


Supplementary notes

* Currently, the Northwest Territories and Nunavut do not submit data to NPDUIS.
** Spending on antivirals for treatment of hepatitis C infections in Prince Edward Island is not included in NPDUIS.
*** Spending on ranibizumab and aflibercept (which accounted for 99.9% of spending on antineovascularization agents) in Nova Scotia, Manitoba and British Columbia, and the majority of this spending in Alberta, is funded through special programs and is not included in NPDUIS.
**** The majority of spending on PKIs in Saskatchewan, Alberta and British Columbia is not funded through public drug programs and is not included in NPDUIS.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Canadian pharmaceutical industry"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.